. Absent adaptive, individualized dose-finding in early-phase Background oncology trials, subsequent 'confirmatory' Phase III trials risk suboptimal dosing, with resulting loss of statistical power and reduced probability of technical success for the investigational therapy. While progress has been made toward explicitly adaptive dose-finding and quantitative modeling of dose-response relationships, most such work continues to be organized around a concept of 'the' maximum tolerated dose (MTD). The purpose of this paper is to demonstrate concretely how the aim of early-phase trials might be conceived, not as 'dose-finding', but as -finding. dose titration algorithm (DTA) A Phase I dosing study is simulated, for a notional cytotoxic Methods. chemotherapy drug, with neutropenia constituting the critical dose-limiting toxicity. The drug's population pharmacokinetics and myelosuppression dynamics are simulated using published parameter estimates for docetaxel. The amenability of this model to linearization is explored empirically. The properties of a simple DTA targeting neutrophil nadir of 500 cells/mm using a Newton-Raphson heuristic are explored through simulation in 25 simulated study subjects.
Introduction
Despite advances in Bayesian adaptive designs 1,2 and model-based dose-finding 3 , oncology dose-finding studies remain conceptually in the thrall of 'the' maximum tolerated dose (MTD). This fallacious concept stands opposed to the long-recognized heterogeneity of cancer patients' pharmacokinetics and pharmacodynamics (PK/PD), and to the diversity of their individual values and goals of care. Under this conceptual yoke, these dose-finding studies constitute a significant choke-point in drug development, where a severe discount may be applied to the potential value in new molecules through the hobbling of subsequent 'efficacy' trials by inadequate individual-level dosing 4 .
Strangely, Bayesian innovation in dose-finding studies has proceeded apace without issuing a meaningful challenge to the inherently frequentist conception of an MTD as determined by whole-cohort frequencies of dose-limiting toxicities (DLTs). Thus, even as Bayesianism has made progress toward the ethical imperative of efficient use of data 5 in such studies, it has neglected to confront the distinct ethical dimension of individualism 6 . This seems a great irony, as the dynamic learning model of Bayesianism is equally suited, and indeed equally essential, to solving the latter problem.
This paper demonstrates individualized dose-finding in a simulated Phase I study of a cytotoxic chemotherapy drug for which neutropenia constitutes the critical dose-limiting toxicity. Importantly, myelosuppression is interpreted also as a monotone index of therapeutic efficacy, without the added complication of a dose-response 'plateau' 7 such as postulated for molecularly targeted agents (MTAs). This creates a problem setting where simple heuristics apply, simplifying the demonstration undertaken here. The aim of this exercise is to elaborate a concrete setting in which 'dose-finding study' may readily be seen as a misnomer. Under the view advanced here, early-phase studies of this kind should be conceived as dose titration algorithm tuning (DTAT) studies.
The idea that 'dose finding studies' should yield dose titration algorithms (DTAs) is not new. More than a quarter-century ago, Sheiner and colleagues 8 advocated a learn-as-you-go concept for "doseranging studies", addressing concerns about "parallel-dose designs" that are not far removed from the motivations for the present paper. As in the advocacy of Sheiner et al., parametric models play an important role in this paper, although in keeping with a spirit of pragmatism I relax this dependence to some extent by means of a semiparametric dynamic on-line learning heuristic.
Methods
A hypothetical cytotoxic drug is considered, modeled notionally after docetaxel, to be infused in multiple 3-week cycles. The pharmacokinetics are taken to follow a 2-compartment model with parameters as estimated for docetaxel in a recent population pharmacokinetic study 9 . Chemotherapy-induced neutropenia (CIN) is taken to follow a myelosuppression model due to Friberg et al. 10 . Together, these models form a population pharmacokinetic/ pharmacodynamic (PK/PD) model within which DTAs may be simulated and tuned for optimality. For simulation purposes, and anticipating the future value of ready access to a variety of inference procedures in follow-on work, this PK/PD model is implemented in R package pomp
11
. R version 3.3.2 was used 12 .
Basic behaviors of the models are illustrated by simulation graphics generated for 25 individuals randomly generated from the population PK/PD model. Properties with specific relevance to absolute neutrophil count nadir (ANCnadir)-targeted dose titration are then investigated, with an eye to demonstrating the predictability of nadir timing. In particular, an approximate linearization of neutrophil nadir level and timing is demonstrated, achieved through suitable power-law transformation of infusion doses and logarithmic transformation of neutrophil concentration. Within this transformed parameter space, a simple recursive DTA is defined on the basic heuristic of the Newton-Raphson method for root-finding. For simplicity, monitoring of CIN is not modeled endogenously to this algorithm, but is treated as exogenous such that nadir timing and level are known precisely. A 'DTAT' study is simulated and visualized for 25 patients, with the tuning parameters of the recursive titration algorithm held fixed. The visualization supports a discussion of how these parameters might be tuned over the course of a Phase I study. All simulations and figures in this paper were generated by a single R script, archived on OSF 13 .
Pharmacokinetic model
We take the population pharmacokinetics of our cytotoxic drug to obey a 2-compartment model, with parameters drawn notionally from estimates published for docetaxel [9, Table 2 ]; see Table 1 .
Amendments from Version 1
Changes in v2, stimulated largely by Dr. Natalja Strelkowa's reviewer comments, follow closely my posted reply. Chiefly, I have sought in v2 to separate the merely incidental aspects of the concrete simulation here presented from the essential content of the DTAT principle. In particular, (a) I now directly contrast DTAT's dose titration algorithm abstraction against the fallacious abstraction of 'the' MTD, introducing the separate acronym 'DTA' specifically for added emphasis, and indicating a connection with Karl Popper's concept of objective knowledge; (b) I stress that recursive filtering methods (such as the Kalman filter) have contributed heuristically to DTAT, but in no way delimit or define DTAT; (c) I discuss at some length (adding 3 new citations) how the DTAT principle applies beyond cytotoxic chemotherapy as simulated here -specifically, to cancer immunotherapies and molecularly targeted agents; model-based dose titration 15 . Indeed, the 'tuning' in 'DTAT' was itself suggested by the practice of tuning a Kalman filter 16 for optimal performance.
For present purposes, however, it suffices to implement a modelfree recursive titration algorithm built on the Newton-Raphson method, with a numerically-estimated derivative based on most recent infusion doses and their corresponding ANC nadirs. In this algorithm, a relaxation factor ω = 0.75 is applied to any proposed dose increase, with safety in mind. Whereas the slope of log(ANC nadir ) with respect to 4 dose is expected to be strictly negative at steady state, hysteresis effects arising during initial steps of dose titration do sometimes yield positive numerical estimates for this slope; so the slope estimates are constrained to be ≤ 0. The infusion dose for cycle 1 is 50 mg, and the cycle-2 dose is calculated conservatively using a slope −2.0, which is larger (in absolute terms) than for any of our simulated patients except id1 and id13; see Figure 4 . For reference, these starting values for the tuning parameters of the titration algorithm are collected in Table 3 .
With the illustrative purpose of this article again in mind, we treat neutropenia monitoring as an exogenous process yielding precise nadir timing and levels. This enables a demonstration of the main point without the encumbrance of additional modeling infrastructure peripheral to the main point.
On 'tuning'
If one considers Figure 5 as a sequence of titration outcomes emerging in serially enrolled study subjects, it becomes clear that even quite early in the study it will seem desirable to 'retune' the titration algorithm. For example, provided that course-1 CIN monitoring is implemented with sufficient intensity to deliver advance warning of an impending severely neutropenic nadir, so that timely colony-stimulating factor may be administered prophylactically 17 , then upon review of the titration courses in the first 10 subjects it may well appear desirable to increase dose 1 from 50mg to 100mg. Likewise, given the third-dose overshooting that occurs in 4 of the first 10 subjects, it may seem desirable to adjust the relaxation factor ω downward. Of note, at any given time any such proposed retuning may readily be subjected to a 'dry run' using retrospective data from all convergent titration courses theretofore collected. (Hysteresis effects would however be inaccessible to a strictly data-driven dry run absent formal modeling that captures such effects.) Furthermore, the 'tuning' idea readily generalizes to the fundamental modification or even wholesale replacement of a DTA. For example, the overshooting seen for subjects id8, id10, id12 and id23, inspires further thought about refining (or replacing) the admittedly very naive Newton-Raphson method employed herein. (At the very least, DTAs deployed in actual DTAT studies must incorporate fail-safe upper bounds both on absolute dose and on proportional dose increases.)
A further dimension of 'tuning' that must be discussed is the potential for driving the tuning parameters using statistical models built on baseline covariates. Surely, to the extent that the great heterogeneity in final dosing evident in Figure 5 could be predicted based on age, sex, weight or indeed on pharmacogenomic testing, then dose 1 should be made a function of these covariates. The recalibration of such models as data accumulate from successive study subjects is very much a part of the full concept of 'tuning' I wish to advance.
Finally, whereas I have discussed 'tuning' here largely in terms of reflective, organic decision-making such as occurs in the creative refinement of algorithms or in data-driven statistical model development, I do not mean to exclude more formal approaches to algorithm tuning. A decision-theoretic framing of the tuning problem should enable formal algorithm tuning to be specified and carried out meaningfully. Such framing would also have the salutary effect of bringing into view objectively the important matter of patients' heterogeneity with respect to values and goals of care. It seems quite likely that the balance of benefits from aggressive titration versus harms of toxicities will generally differ from one patient to another. Dose titration algorithms should most emphatically be tuned to these factors as well. For example, if a patient with more advanced disease and short expected survival nevertheless decided to enroll in a Phase I DTAT study to pursue the possibility of therapeutic benefit, then this patient's decision would indicate a subjective weighting of benefits vs. harms favoring a higher starting dose and more aggressive titration.
Discussion
It is where pharmacometrics meets the field of optimal control that the current literature seems to make its closest point of contact with the DTAT concept I am advancing here. In optimal-control investigations of chemotherapy [18] [19] [20] [21] [22] [23] , as in DTAT, relatively large decision spaces are explored. Indeed, the infinite-dimensional spaces of control functions posited for exploration in optimal control applications dwarf the finite-dimensional spaces of tuning parameters in DTAT as dramatically as the latter dwarf the finite sets of discrete doses trialed in now-standard Phase I studies. This intermediate 'cardinality' of DTAT reflects an important advantage in an era when, to almost universal chagrin, the detested 3+3 dosefinding design retains its hegemony due partly to widespread resistance to modeling 24 . In such an era, optimal control applications that involve detailed mathematical modeling of tumor biology and dynamics sadly seem consigned to the fringes of practice. Acceptance of such ambitious problem formulations, expressing as they do the spirit of a future age, must await deep cultural changes in the medical sciences and clinical practice.
As easy as it is, however, to disparage 'resistance to modeling' as some kind of antediluvian attitude, this resistance does rightfully assert the importance of unmodeled complexities that necessitate application of organic forms of clinical judgment 25 . It should be clear from the above discussion of 'tuning' that DTAT readily accommodates and veritably invites scrutiny, supervision and modification by clinical judgment. For example, if during the course of our DTAT study adverse effects other than neutropenia were to emerge as occasional dose-limiting toxicities, then the full concept of 'tuning' advanced above would invite dynamic, 'learn-as-you-go' modifications of the titration algorithm. Such modifications could begin with decreasing the relaxation factor ω, but might also involve efforts to classify and predict these new DLTs, and to incorporate such new understanding explicitly into the DTA yielded by the study. Indeed, whatever philosophical challenge DTAT embodies is likely to take the form of requiring an intensified commitment to clinical judgment, in a learn-as-you-go world where the always-provisional nature of medical knowledge must frankly be acknowledged 6, 26 . I have presented the DTAT principle here embedded in the context of a specific simulation study. This creates the need explicitly to demarcate what I wish to advance as essential in DTAT, from what is merely incidental to the illustration offered here. DTAT makes its fundamental contribution in putting forward a new abstraction (the DTA with its tuning parameters) capable of embodying knowledge objectively 27 , to supersede a fallacious abstraction ('the' MTD) that almost completely lacks this capability. I use the term fallacious advisedly, meaning to identify 'the' MTD specifically with what Whitehead called the "fallacy of misplaced concreteness [which] consists in neglecting the degree of abstraction involved when an actual entity is considered merely so far as it exemplifies certain categories of thought 28 ." Indeed, the 1.5 orders of magnitude spanned by the MTD i s of Figure 5 show the degree of abstraction involved in 'the' MTD to be so egregious as to render this concept plainly useless for embodying what we need to learn from Phase I oncology studies.
Several aspects of the illustration offered here should be clearly understood as not essential to the DTAT principle. Firstly, notwithstanding the important heuristic role it has played in the development (and even the naming) of DTAT, recursive filtering in no way delimits DTAT. In fact, I now rather suspect that fullinformation methods will push recursive filtering to the sidelines in practical DTAT applications, and that whatever utility recursive filtering retains will derive from its use as a vehicle for illustrating DTAT to clinicians, perhaps in nomogram forms 15 . Secondly, although neutropenia-targeted dosing of a cytotoxic chemotherapy drug has provided a most propitious context for the present simulation, DTAT need not be thought limited to such drugs. In the important area of immuno-oncology, common dose-limiting toxicities (DLTs) admit monitoring on time-scales comparable to the chemotherapy induced neutropenia (CIN) simulated here. For example, the cytokine release syndrome (CRS) that accompanies chimeric antigen receptor (CAR-)T cell therapies typically arises within 1 week of administration (even earlier with concomitant high-dose IL-2) and constitutes a clinical syndrome that admits multivariate monitoring on numerous quantitative clinical and laboratory measures 29 . Even molecularly targeted agents (MTAs), for which late toxicities have attracted the lion's share of attention 30 , remain accessible to the DTAT principle-with DTA learning occurring on a longer time scale. Of course, a DTA that reacts to diverse, lower-grade MTA toxicities 31 that patients experience and evaluate subjectively may resemble a process of ongoing shared decision making (with the oncology care team) more closely than it resembles the impersonal calculations we typically think of as 'algorithmic'. But with a suitably broadened understanding of 'algorithm'-one that accommodates what might typically be termed protocols-the DTAT (or perhaps, DTPT) principle continues to apply. In such applications, supervision and modification by clinical judgment as mentioned above clearly comes to the fore. But even then, the development and application of scoring systems for patientreported clinical symptoms and quality of life would enable dose titration protocols (DTPs) to be described objectively in quite 'algorithmic' terms that would preserve the applicability of a 'tuning' concept.
Conclusions
I have advanced a concept of dose titration algorithm tuning (DTAT), drawing illustrative and orienting connections with recursive filtering and optimal control. I have concretely illustrated key elements of DTAT by simulating neutrophil-nadir-targeted titration of a hypothetical cytotoxic chemotherapy drug with pharmacokinetics and myelosuppressive dynamics patterned on previously estimated population models for docetaxel. I have also discussed the applicability of DTAT to other types of anti-cancer therapy. I believe DTAT presents a prima facie case for discarding the outmoded concept of 'the' maximum tolerated dose (MTD) of cancer therapeutics. This argument should be of interest to a wide range of stakeholders, from cancer patients with a stake in receiving optimal individualized 'MTD i' dosing, to shareholders in pharmaceutical innovation with a stake in efficient dose-finding before Phase III trials. 
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, David Norris Consulting, LLC, USA David C. Norris I thank Dr. Strelkowa greatly for her supportive and critical comments, which invite extended discussion on several points that v1 of this paper has omitted . I use this reply to to its detriment indicate changes I propose to make in v2, pursuant to Dr. Strelkowa's comments. Unless otherwise indicated, these changes would seem to belong in the section: Discussion Dr. Strelkowa rightly points to general conditions that constrain the time-scale on which DTAT-based learning may operate. Specifically, DTAT cannot learn faster than the lag-time at which the targeted toxic response(s) develop. In the important area of immuno-oncology that Dr. Strelkowa highlights, common dose-limiting toxicities (DLTs) do admit monitoring on time scales comparable to the chemotherapy induced neutropenia (CIN) simulated in this paper. For example, the (CRS) that accompanies chimeric cytokine release syndrome antigen receptor (CAR-)T cell therapies typically arises within 1 week of administration (even earlier with concomitant high-dose IL-2) and constitutes a clinical that syndrome admits multivariate monitoring on numerous quantitative clinical and laboratory measures.
[1] Regarding however the molecularly targeted agents (MTAs) also mentioned by Dr. Strelkowa, toxicities indeed have tended to attract the lion's share of attention.
[2] late One reason for this is that the early toxicities of MTAs tend to be relatively milder than those of cytotoxic and immunologic therapies.
[3] Nevertheless, a DTAT principle continues to apply here-just on a longer time scale. Of course, a 'dose titration (DTA) that algorithm' responds to MTA toxicities that patients mainly may experience and evaluate subjectively resemble a process of ongoing (with the oncology care team) more shared decision making than it resembles the impersonal calculations we typically think of as 'algorithmic'. But with a than it resembles the impersonal calculations we typically think of as 'algorithmic'. But with a suitably broadened understanding of 'algorithm'-one that accommodates what might typically be termed -the DTAT (or perhaps, DT T) principle continues to apply. protocols P In such applications, "supervision and modification by clinical judgment" as mentioned in the clearly comes to the fore. But even in such contexts, the development and Discussion application of scoring systems for patient-reported clinical symptoms and quality of life would enable dose titration rotocols (DT s) to be described objectively in quite p P 'algorithmic' terms that would preserve the applicability of a 'tuning' concept.
The issue of Dr. Strelkowa raises is truly important, and brings into play the competing risks inter-individual heterogeneity in "values and goals of care" that I discussed in opening the and (especially) toward the end of the section, where I explicitly Introduction On 'tuning' highlight values/goals as factors that should "most emphatically" inform DTA tuning. (In the PDF, this utterly essential point tragically breaks across pages 7-9 due to an intervening page 8 of figures, a mishap I will aim to avoid in v2.) To address Dr. Strelkowa's comment here, I plan to expand that latter discussion explicitly to incorporate . For example, prognosis if a patient with more advanced disease and short expected survival has (in consultation with the oncologist and oncology care team) nevertheless decided to enroll in a Phase I DTAT study to pursue the possibility of therapeutic benefit, then this patient's decision indicates a subjective weighting of benefits vs harms favoring a and higher starting dose . more aggressive titration I agree that any sound dose titration algorithm will incorporate fail-safe limits on dose escalation. To support a richer discussion in the section, I purposely chose On 'tuning' 'wrong' tuning parameters (and a naive Newton-Raphson DTA) so that Figure 5 would illustrate several problems that one would never purposely 'design in' to an actual study: (a) a too-low starting dose and (b) the potential for overshooting, such as occurred in id8, id10, id12 and id23-the last of whom received in fact an off-scale dose. For v2, in both the Figure 5 caption and the main text of , I propose to note the important role that On 'tuning' on both and will play in reducing fail-safe upper bounds absolute dose dose multipliers the risk of overshooting in a practical trial.
A larger point about DTAT requires clarification in v2. The technical connections with recursive and , as drawn in the paper, serve much the same purpose as filtering optimal control notional choosing docetaxel as the basis for simulation. The above discussion shows the DTAT principle applicable to oncology therapeutics beyond the cytotoxics. Likewise, notwithstanding the essential heuristic role has played in DTAT's development, it should not be thought to recursive filtering define DTAT. (In fact, I have at this point in my further work already abandoned the linear Kalman filter approach indicated in the last sentence of v1 , in favor of full-information methods.) Abstract What define DTAT's essential contribution to Phase I oncology study design is that it yields a does (the with its ) capable of new abstraction DTA tuning parameters embodying knowledge [4], to supersede a ('the' MTD) that almost completely lacks objectively fallacious abstraction this capability. I must make this point explicit in v2, emphasizing that the role of the technical connections I've drawn is the abstraction which constitutes DTAT's to illustrate (DTA+tuning) essential contribution. I will also try to modify the title somehow to underscore this point. I will however retain a withering treatment of 'the' MTD, an anti-precision idea whose time has passed. In support of that view, I will in the v2 or briefly discuss 'the' MTD Discussion Introduction specifically as a [5] . The purpose of my strong title is fallacy of misplaced concreteness to Should any clinical trial methodologist provoke long-overdue critical thought and discourse. leap now to the defense of 'the' MTD, I will most heartily welcome that challenge.
